Efficacy and safety of PD-1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study.
Junlin YaoXudong ZhuZhiheng WuQing WeiYibo CaiYu ZhengXinyu HuHong HuXiangyu ZhangHongming PanXian ZhongWeidong HanPublished in: Cancer medicine (2022)
We elucidated the efficacy and safety of immunotherapy-antiangiogenesis combination therapy and identified potential predictors for response and survival in a real-world cohort of patients with unresectable HCC.